Literature DB >> 24326762

The economic burden of hemodialysis in Jordan.

Emad Adel Al-Shdaifat1, Mohd Rizal Abdul Manaf.   

Abstract

BACKGROUND: Hemodialysis treatment is a costly procedure that requires specific resources. It has a considerable burden on patients, caregivers, and healthcare system. The aim of this study was to estimate the economic burden borne by the Ministry of Health (MOH) in Jordan, with a focus on direct medical, direct non-medical, and indirect cost.
MATERIALS AND METHODS: The study was conducted at MOH hospitals in Jordan, from August to November 2010. A total of 138 patients and 49 caregivers were involved in the study. An economic evaluation study was used to analyze the burden of hemodialysis treatment at MOH, Jordan. Direct medical costs were estimated through micro and macro costing from the provider's perspective. Patients' and caregivers' costs were included to calculate direct non-medical costs. Human capital approach was employed to evaluate the productivity loss for indirect cost and premature death and potential year life loss was used to estimate the premature death cost.
RESULTS: The total burden of hemodialysis at MOH, Jordan was USD17.70 million per year. Cost per session was $72 and the annual cost per patient was $9976. Direct medical cost was $7.20 million (41%) and direct non-medical cost was $2.02 million (11%). On the other hand, indirect cost (productivity loss) was $8.48 million (48%). All 722 patients on hemodialysis at MOH hospitals consumed 2.7% of MOH budget.
CONCLUSIONS: Costs of treating and managing patients on hemodialysis at MOH hospitals in Jordan are substantial. Therefore, efforts should be taken to slow down the progress of renal failure to save resources and a comparative study with other modalities, such as continuous ambulatory peritoneal dialysis and kidney transplantation, should be considered.

Entities:  

Mesh:

Year:  2013        PMID: 24326762

Source DB:  PubMed          Journal:  Indian J Med Sci        ISSN: 0019-5359


  7 in total

1.  Pharmacoeconomic evaluation of hospitalised pre-dialysis and dialysis patients: A comparative study.

Authors:  Uday Venkat Mateti; Anantha Naik Nagappa; Santosha Vooradi; Marijana Madzaric; Aswani Srinivas Mareddy; Ravindra Prabhu Attur; Shankar Prasad Nagarapu
Journal:  Australas Med J       Date:  2015-04-30

Review 2.  Costs associated with management of non-communicable diseases in the Arab Region: a scoping review.

Authors:  Shadi Saleh; Amena El Harakeh; Maysa Baroud; Najah Zeineddine; Angie Farah; Abla Mehio Sibai
Journal:  J Glob Health       Date:  2018-12       Impact factor: 4.413

3.  Burden, coping mechanisms, and quality of life among caregivers of hemodialysis and peritoneal dialysis undergoing and renal transplant patients.

Authors:  M Nagarathnam; Vishnubotla Sivakumar; S A A Latheef
Journal:  Indian J Psychiatry       Date:  2019       Impact factor: 1.759

4.  The Lived Experience of Primary Family Caregivers of Patients on Hemodialysis Treatment in Southern Ethiopia: A Phenomenological Study.

Authors:  Amene Abebe; Aseb Arba; Kebreab Paulos; Wogayehu Abera; Temesgen Sidamo; Shimelis Shiferaw; Zinabu Abraham; Daniel Baza; Banchialem Nega; Selamawit Woldeyohannes
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-02-22

Review 5.  Prevalence of chronic kidney disease and associated factors among patients with chronic illness in Ethiopia: A systematic review and meta-analysis.

Authors:  Zelalem Animaw; Gashaw Walle Ayehu; Hussen Abdu
Journal:  SAGE Open Med       Date:  2022-04-17

6.  Three years evaluation of peritoneal dialysis and hemodialysis absorption costing: perspective of the service provider compared to funds transfers from the public and private healthcare systems.

Authors:  Alyne Schreider; Celso Souza de Moraes Júnior; Natália Maria da Silva Fernandes
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

Review 7.  Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review.

Authors:  Elizabeth D Brouwer; David Watkins; Zachary Olson; Jane Goett; Rachel Nugent; Carol Levin
Journal:  BMC Public Health       Date:  2015-11-26       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.